anti-Apolipoprotein A (APOA) Antikörper

The protein encoded by APOA is a serine proteinase that inhibits the activity of tissue-type plasminogen activator I. Zusätzlich bieten wir Ihnen Apolipoprotein A Kits (14) und Apolipoprotein A Proteine (4) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID
APOA 4018
APOA  
Direkt bei antikoerper-online bestellen
  • +49 (0)241 95 163 153
  • +49 (0)241 95 163 155
  • Online bestellen
  • orders@antikoerper-online.de

Top anti-Apolipoprotein A Antikörper auf antikoerper-online.de

Showing 10 out of 47 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Anbieter Lieferzeit Preis Details
Human Kaninchen Unkonjugiert WB <b>WB Suggested Anti-LPA Antibody Titration: </b>0.2-1 ug/ml<br><b>ELISA Titer: </b>1:312500<br><b>Positive Control: </b>Jurkat cell lysate WB Suggested Anti-LPA <br /> Antibody Titration: 0.2-1 µg/mL ELISA Titer: 1:.12500 <br /> Positive Control: Jurkat cell lysate 100 μL Anmelden zum Anzeigen 6 bis 8 Tage
358,51 €
Details
Human Kaninchen Unkonjugiert WB <b>WB Suggested Anti-LPA Antibody Titration: </b>0.2-1 ug/ml<br><b>ELISA Titer: </b>1:312500<br><b>Positive Control: </b>Jurkat cell lysate WB Suggested Anti-LPA <br /> Antibody Titration: 0.2-1 µg/mL ELISA Titer: 1:.12500 <br /> Positive Control: Jurkat cell lysate 100 μL Anmelden zum Anzeigen 6 bis 8 Tage
358,51 €
Details
Human Maus Unkonjugiert ICC, IHC, ELISA, WB Figure 1: Red: Control Antigen (100 ng), Purple: Antigen (10ng), Green: Antigen (50 ng), Blue: Antigen (100 ng) Figure 2: Immunofluorescence analysis of HepG2 cells using LPA mouse mAb (green) . Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin. 0.1 mg Anmelden zum Anzeigen 6 bis 8 Tage
494,23 €
Details
Human Maus Unkonjugiert IHC, ELISA, WB Figure 1: Immunohistochemical analysis of paraffin-embedded human Liver tissues using LPA mouse mAb Figure 2: Western blot analysis using LPA mouse mAb against truncated LPA-His recombinant protein (1) and truncated Trx-LPA (aa4330-4521) recombinant protein (2) . 100 μL Anmelden zum Anzeigen 6 bis 8 Tage
453,56 €
Details
Human Maus Unkonjugiert EIA, IHC (p), WB 50 μL Anmelden zum Anzeigen 7 bis 9 Tage
517,00 €
Details
Human Ziege Unkonjugiert EIA, IHC (p) Human Liver (formalin-fixed, paraffin-embedded) stained with LPAfollowed by biotinylated anti-goat IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen. 0.1 mg Anmelden zum Anzeigen 7 bis 9 Tage
517,00 €
Details
Human Maus Unkonjugiert IHC, ELISA, WB   0.1 mL Anmelden zum Anzeigen 8 bis 11 Tage
419,05 €
Details
Säugetier Schaf Unkonjugiert EIA, WB   1 mg Anmelden zum Anzeigen 7 bis 9 Tage
649,00 €
Details
Human Schaf Unkonjugiert ELISA, WB   1 mg Anmelden zum Anzeigen 7 bis 9 Tage
615,10 €
Details
Human Ziege Unkonjugiert ID   0.5 mL Anmelden zum Anzeigen 7 bis 9 Tage
385,00 €
Details

APOA Antikörper nach Reaktivität, Anwendung, Klonalität and Konjugat

Attribute Applikationen Wirt Klonalität Konjugat
Human , , , ,
, , ,
,
, ,
Mammalian


Am meisten referenzierte anti-Apolipoprotein A Antikörper

  1. Human Monoclonal APOA Primary Antibody für ICC, IHC - ABIN969533 : Nicholls, Tang, Scoffone, Brennan, Hartiala, Allayee, Hazen: Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. in Journal of lipid research 2010 (PubMed)
    Show all 2 Pubmed References

  2. Human Monoclonal APOA Primary Antibody für IHC, ELISA - ABIN969261 : Ranga, Kalra, Tandon, Gambhir, Mehrotra: Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2007 (PubMed)
    Show all 2 Pubmed References

  3. Human Monoclonal APOA Primary Antibody für IHC, ELISA - ABIN966490 : : USA: bringing reality to the great American tobacco show. in Tobacco control 2007 (PubMed)
    Show all 2 Pubmed References

Weitere Antikörper gegen Apolipoprotein A Interaktionspartner

Human Apolipoprotein A (APOA) Interaktionspartner

  1. Report high lipoprotein(a) levels in Sri (zeige SRI Antikörper) Lankan patients awaiting coronary artery bypass.

  2. Treatment of mildly hypercholesterolemic subjects with CETP (zeige CETP Antikörper) inhibitor anacetrapib reduces Lp(a) levels by decreasing its production.

  3. Structure, function, and genetics of Lp(a) with emphasis on the molecular and population genetics of the Lp(a)/LPA trait, as well as aspects of genetic epidemiology. [review]

  4. Due to new therapies that lower Lp(a) levels, there is renewed interest and still rising research activity in Lp(a). Despite all these activities, numerous gaps exist in our knowledge, especially as far as the function and metabolism of this fascinating Lp are concerned.

  5. This discovery has sparked intense interest in Lp(a) as a modifiable cause for aortic valve disease. Herein, we will review the mounting epidemiological and genetic findings in support of Lp(a)-mediated valve disease, discuss potential mechanisms underlying this observation, and outline the steps to translate this discovery to a much needed novel preventive and/or therapeutic strategy for aortic valve disease.

  6. Levels of lipoprotein (a) [Lp(a)], a complex between an LDL-like lipid moiety containing one copy of apoB (zeige APOB Antikörper), and apo(a), a plasminogen (zeige PLG Antikörper)-derived carbohydrate-rich hydrophilic protein, are primarily genetically rIncreasing evidence suggests that age, sex, and hormonal impact may have a modest modulatory influence on Lp(a) levels. Among clinical conditions, Lp(a) levels are reported to be affected by kidney and liver diseases.

  7. these studies support that reductions in Lp(a) with PCSK9 (zeige PCSK9 Antikörper) inhibition are partly due to increased LDLR (zeige LDLR Antikörper)-mediated uptake. In most situations, Lp(a) appears to compete poorly with LDL for LDLR (zeige LDLR Antikörper) binding and internalization, but when LDLR (zeige LDLR Antikörper) expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a) is reduced.

  8. Elevated Lp(a) level was an independent predictable risk factor for cardiovascular disease in type 2 diabetes.

  9. Recent genetic evidence documents elevated Lp(a) as a cause of myocardial infarction, atherosclerotic stenosis, and aortic valve stenosis

  10. APOE (zeige APOE Antikörper) genotypes strongly influence Lp(a) and apoB (zeige APOB Antikörper)-related lipoprotein levels.

Apolipoprotein A (APOA) Antigen-Profil

Protein Überblick

The protein encoded by this gene is a serine proteinase that inhibits the activity of tissue-type plasminogen activator I. The encoded protein constitutes a substantial portion of lipoprotein(a) and is proteolytically cleaved, resulting in fragments that attach to atherosclerotic lesions and promote thrombogenesis. Elevated plasma levels of this protein are linked to atherosclerosis. Depending on the individual, the encoded protein contains 2-43 copies of kringle-type domains. The allele represented here contains 15 copies of the kringle-type repeats and corresponds to that found in the reference genome sequence.

Genbezeichner und Symbole assoziert mit APOA

  • lipoprotein, Lp(a) (LPA) Antikörper
  • AK38 Antikörper
  • Apo(a) Antikörper
  • APOA Antikörper
  • LP Antikörper
  • Lp(a) Antikörper

Bezeichner auf Proteinebene für APOA

antiangiogenic AK38 protein , apo(a) , apolipoprotein(a) , lp(a)

GENE ID SPEZIES
4018 Homo sapiens
709528 Macaca mulatta
Ausgewählte Anbieter für anti-Apolipoprotein A (APOA) Antikörper
Haben Sie etwas anderes gesucht?